Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

GTXI:US

1.0800 USD 0.0200 1.82%

As of 20:10:00 ET on 05/22/2015.

Snapshot for GTx Inc (GTXI)

Open: 1.1100 Day's Range: 1.0300 - 1.1500 Volume: 107,940
Previous Close: 1.1000 52wk Range: 0.4100 - 1.7000 1-Yr Rtn: -21.17%

Stock Chart for GTXI

No chart data available.
  • GTXI:US 1.0800
  • 1D
  • 1M
  • 1Y
1.1000
Interactive GTXI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GTXI

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.3558
Est. EPS (USD) (12/2015) -0.1400
Est. PEG Ratio -
Market Cap (M USD) 151.60
Shares Outstanding (M) 140.37
30 Day Average Volume 272,021
Price/Book (mrq) 9.5378
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GTXI

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for GTXI

GTx, Inc. discovers, develops, and commercializes therapeutics primarily related to the treatment of serious men's health conditions. The Company's drug discover and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is currently developing products for prostate cancer.

Robert J Wills "Rob"ChairmanMarc S HanoverPresident/CEO/COO/Co-Founder
Henry P DoggrellVP/Chief Legal Officer/SecyJeffrey G HesselbergVP:Regulatory Affairs
More Company Profile & Key Executives for GTXI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil